Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package

By: Quiver PriceTracker

Posted: 7 hours ago / Aug. 6, 2026 2:57 p.m. UTC

ENSC

Ensysce Biosciences, Inc. (ENSC) is up 75.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to Ensysce’s announcement that it completed the acquisition of Cy Biopharma alongside a financing package that could bring in as much as $77 million. Investors likely reacted to the added cash, the new clinical-stage pain asset CY200, and the possibility that the combined company now has a clearer funding path into key trial milestones.

Details:

Ensysce said the transaction adds Cy Biopharma, whose lead program CY200 is being developed for Complex Regional Pain Syndrome, a severe chronic pain condition with no approved therapy.

The company outlined funding of up to $77 million, including about $21.5 million expected at the initial private placement close, $17.1 million of cash tied to Cy Biopharma before the acquisition, and a potential follow-on tranche linked to a clinical milestone.

Management indicated the combined cash position is expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development, which may have eased concerns about near-term financing risk.

The announcement also highlighted U.S. orphan drug status for CY200 and named several healthcare-focused investors in the financing, which may have reinforced confidence in the transaction.

Sources:

Ensysce Biosciences Investor Relations, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ENSC Hedge Fund Activity

We have seen 10 institutional investors add shares of $ENSC stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DRW SECURITIES, LLC removed 98,481 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $53,032
ADAGE CAPITAL PARTNERS GP, L.L.C. added 75,000 shares (+100.4%) to their portfolio in Q1 2026, for an estimated $40,387
CITADEL ADVISORS LLC added 57,363 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,889
GEODE CAPITAL MANAGEMENT, LLC added 51,790 shares (+234.4%) to their portfolio in Q1 2026, for an estimated $27,888
HRT FINANCIAL LP removed 24,491 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $13,188
XTX TOPCO LTD added 24,363 shares (+inf%) to their portfolio in Q1 2026, for an estimated $13,119
FINANCIAL PLAN, INC. removed 24,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,924

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.